Levofloxacine Viatris (Levofloxacin)

Levofloxacine Viatris is a fluoroquinolone antibiotic indicated for several bacterial infection categories.

• Urinary tract infections: eradicates susceptible Gram‑negative and Gram‑positive pathogens causing uncomplicated and complicated UTIs.
• Community‑acquired respiratory tract infections: treats pneumonia, bronchitis and other lower respiratory infections caused by susceptible organisms.
• Skin and soft‑tissue infections: effective against cellulitis, abscesses and wound infections due to susceptible bacteria.
• Acute bacterial prostatitis: resolves infection of the prostate gland caused by levofloxacin‑sensitive strains.
• Complicated intra‑abdominal infections: used as part of combination therapy for polymicrobial intra‑abdominal infections.

• Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to these targets, it prevents DNA synthesis and transcription, leading to bacterial cell death. The drug exhibits concentration‑dependent bactericidal activity against a broad spectrum of Gram‑negative and Gram‑positive organisms.

Levofloxacine Viatris may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Dizziness: sensation of light‑headedness.
• Abdominal pain: cramping or discomfort in the stomach area.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur during or after therapy.
• QT interval prolongation: risk of cardiac arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile infection: severe colitis following disruption of gut flora.
• Peripheral neuropathy: numbness or tingling in extremities.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.

Levofloxacine Viatris requires careful patient assessment before use.

• Renal function assessment: adjust dose in patients with impaired clearance.
• Tendon disorder avoidance: do not use in patients with a history of tendon disease or recent corticosteroid therapy.
• Cardiac monitoring: avoid in individuals with known QT prolongation or electrolyte disturbances.
• Hypersensitivity vigilance: discontinue if signs of severe allergic reaction appear.
• Pregnancy and lactation: use only if benefits outweigh potential risks, after professional consultation.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levofloxacine Viatris can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Concomitant fluoroquinolones: additive toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of CNS stimulation.
• Antacids containing magnesium or aluminum: reduced levofloxacin absorption.
• Warfarin: enhanced anticoagulant effect, monitor INR closely.
• Cyclosporine: elevated cyclosporine serum concentrations.

Moderate Interactions (Monitor Closely)

• Oral hypoglycemic agents: potential for hypoglycemia.
• Theophylline: increased plasma levels, risk of toxicity.
• Corticosteroids: heightened risk of tendon rupture.
• Sulfonylureas: possible enhanced glucose‑lowering effect.
• Oral contraceptives: reduced hormonal efficacy, consider backup contraception.